Astellas wins FDA nod for antifungal Cresemba
This article was originally published in Scrip
Executive Summary
Astellas won the FDA’s approval to market Cresemba (isavuconazonium sulfate) in the US as a treatment for two rare but serious infections, invasive aspergillosis and invasive mucormycosis.
You may also be interested in...
Pfizer’s Amplyx Buy Continues Infectious Disease Deal-Making Spree
Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.